… multiple myeloma genomes with data linked to clinical outcome has enabled an increased
understanding of the pathogenesis of multiple myeloma in … of patients with multiple myeloma. …

Multiple myeloma (MM) remains an incurable plasma cell malignancy that develops in the
bone marrow (BM). This BM is partially responsible for protecting the MM cells against current …

… to resensitize refractory-multiple myeloma cells in preclinical studies… drugs (proteasome
inhibitors, immunomodulatory drugs and … HDACi for the treatment of multiple myeloma. Here, we …

… therapies from the bench to the bedside. The American … Liquid biopsies have emerged
as a promising tool in MM to … , new immune approaches have become part of MM treatment …

… the way for the discovery of new potential targeted therapies [7]. However, as the population
is living longer, two more concerns are emerging as new unmet clinical needs in AML …

… has emerged as a potential approach for the treatment of MM. Specifically, combination
treatment with HDAC inhibitors and proteasome inhibitors or immunomodulatory drugs shows …

… Fully published phase 2 and randomized, phase 3 trials including new drugs in patients …
of these new drugs in the front-line treatment of MM and the potential impact of these new …

… Over the course of the past decade-plus, the therapy of newly diagnosed multiple myeloma
… and management of newly diagnosed active multiple myeloma, with a focus on major clinical …

… Remarkable progress has been achieved in multiple myeloma, and patient median …
treatments for multiple myeloma in the past 12 years, including seven in 2015, and the treatment …

… is the hallmark of multiple myeloma, which deteriorates the quality of life of myeloma patients,
… During the last years, osteocytes have emerged as key regulators of bone loss in myeloma …